Risk of dementia with combined estrogen-progestin therapy versus placebo

In the Women's Health Initiative Memory Study, after a mean follow-up of four years, HT was associated with an increased risk of dementia (overall HR 2.05, 95% CI 1.21-3.48). Data shown only through five years of follow-up because numbers at risk are too small after this point for precise estimates.

E+P: estrogen + progestin; HR: hazard ratio; HT: hormone therapy.

Data from: Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. JAMA 2003; 289:2651.

Graphic 57042 Version 6.0

خرید پکیج

Risk of dementia with combined estrogen-progestin therapy versus placebo